Treatment of hepatocellular carcinoma by means of radiopharmaceuticals

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 980-989

  Lambert, Bieke ^a   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hepatocellular carcinoma; Iodine 131; Lipiodol; Microspheres; Radio immunotherapy; Rhenium 188; Yttrium 90

Indexed keywords

ANTIINFLAMMATORY AGENT; FLUOROURACIL; HOLIUM 166; HOLMIUM; IODINATED POPPYSEED OIL I 131; IODINE 131; MICROSPHERE; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; TAMOXIFEN; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

COMPUTER ASSISTED TOMOGRAPHY; DATA BASE; DRUG CONJUGATION; FEVER; HUMAN; HYPOCHONDRIASIS; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG SHUNTING; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RANDOMIZATION; RECURRENT DISEASE; REDUCTION; REVIEW; RISK FACTOR; TOXICITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 23944464520     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1859-z     Document Type: Review

References (85)

1. Röcken C, Carll-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001;19:269-78
2. Parkin MD, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer 2001;94:153-6
3. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001;28:441-9
4. Sherman M. Surveillance for hepatocellular carcinoma. Semin Oncol 2001;28:450-9
5. Coackley FV, Schwartz LH. Imaging of hepatocellular carcinima: a practical approach. Semin Oncol 2001;28:460-73
6. Ward J, Robinson PJ. How to detect hepatocellular carcinoma in cirrhosis. Eur Radiol 2002;12:2258-72
7. Caturelli E, Ghittoni G, Roselli P, De Palo M, Anti M. Fine needle biopsy of focal liver lesions: the hepatologist's point of view. Liver Transplant 2004;10:S26-9
8. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004;10:S115-20
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Eng J Med 1996;334:693-699
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42
11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17
12. Dusheiko GM, Hobbs KE, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992;340:285-8
13. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-6
14. Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol 1995;22:522-6
15. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-13
16. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolisation for unresectable hepatocellular carcinoma: meta-analysis of randomised controlled trials. Radiology 2002;224:47-54
17. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 2004;15:427-37
18. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593-603
19. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S319-28
20. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig Dis 2001;19:311-23
21. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503-13
22. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carinoma. Semin Oncol 2001;28:514-20
23. Mathurin P, Rixe O, Bernards B, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-26
24. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15:439-52
25. Cheng JC, Chuang VP, Cheng SH, et al. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemo-embolisation. Int J Cancer 2001;96:243-52
26. Cheng JC, Wud JK, Huanga CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002;63:41-5
27. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-33
28. Seong J, Park HS, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with arterial chemoembolization. Int J Radiat Oncol Biol Phys 2000;47:1331-5
29. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985;154:15-7
30. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cells and endothelial cells incorporate iodised oil. Br J Cancer 1996;73:877-81
31. Al-Mufti RA, Pedley RB, Marshall D, et al. In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br J Cancer 1999;79:1665-71
32. Ho S, Lau WY, Leung TWT, Johnson PJ. Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer 1998;83:1894-907
33. Risse JH, Grünwald F, Kersjes W, et al. Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000;15:65-70
34. 131I Lipiodol therapy for unresectable hepatocellular carcinoma. Aust NZ J Surg 2002;72:210-4
35. I31I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-61
36. 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202-10
37. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-7
38. Brans B, Van Laere K, Gemmel F, et al. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:928-32
39. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-51
40. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial Lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999,353:797-801
41. Pocock S, White I. Trials stopped too early: too good to be true? Lancet 1999;353:943-4
42. Partensky C, Sassolas G, Henry L, Paliard P, Maddern G. Intra-arterial iodine 131-labeled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. A phase 2 clinical study. Arch Surg 2000;135:1298-300
43. Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of I131-labelled Lipiodol. Br J Surg 2003;90:1379-83
44. Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237-41
45. 131I-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001;16:333-8
46. Wall WJ, Marotta PJ. Surgery and transplantation for hepatocellular cancer. Liver Transplant 2000;6:S16-22
47. Monsieurs M, Bacher K, Brans B, et al. Patient dosimetry for 131-I-Lipiodol therapy. Eur J Nucl Med Mol Imaging 2003;30:554-61
48. 131I-Lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003;24:671-8
49. Wang SJ, Lin WY, Chen MN, Shen LH, Tsai ZT, Ting G. Preparation and biodistribution of yttrium-90 Lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 1995;22:233-6
50. Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT, Ting G. Hepatic artery injection of yttrium-90-Lipiodol: biodistribution in rats with hepatoma. J Nucl Med 1996;37:332-5
51. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isotopes 2003;58:567-73
52. 188Re for hepatic tumour therapy. Appl Radiat Isotopes 1996;47:267-71
53. Wang SJ, Lin WY, Chen MN, et al. Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996;23:13-7
54. 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28:197-204
55. 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237-42
56. Sundram FX, Jeong J-M, Zanzonico P, et al. Trans-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002;1:5-11
57. Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2004;31:250-7
58. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 2005;46:60-6
59. 188Re-SSS Lipiodol following injection into the hepatic artery of healthy pigs. Eur J of Nucl Med Mol Imaging 2004;31:542-6
60. 188Re-Lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004;25:691-9
61. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989;172:857-60
62. Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70:2250-4
63. 90ytrrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant 2004;10:S107-10
64. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127:S194-205
65. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994-9
66. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16:195-203
67. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vase Interv Radiol 2005;16:205-13
68. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293-8
69. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90 yttrium-microspheres for inoperable hepatic tumours. Int J Radiat Oncol Biol Phys 1995;33:919-24
70. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vase Interv Radiol 2004;15:335-45
71. Liu L, Jiang Z, Teng GJ, et al. Clinical and experimental study on regional administration of phosphorus 32 microspheres in treating hepatic carcinoma. World J Gastroenterol 1999;5:492-505
72. Häfeli UO, Casillas S, Dietz DW, et al. Hepatic tumour radioembolization in a rat model using radioactive rhenium (Re-186/Re-188) glass microspheres. Int J Radiat Oncol Biol Phys 1999;44:189-99
73. Häfeli UO, Roberts WK, Pauer GJ, Kraeft ST, Macklis RM. Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation. Appl Radiat Isotopes 2001;54:869-79
74. Mumper RJ, Ryo UY, Jay M. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumours. J Nucl Med 1991;32:2139-43
75. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001;28:743-49
76. 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 1993;119:257-9
77. 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998;124:275-80
78. Zeng ZC, Tang ZY, Yang BH, et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1657-68
79. 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991;20:953-63
80. 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 1989;16:319-23
81. Uraki J, Yamakado K, Nakatsuka A, Takeda K. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004;51:12-8
82. 90Y-microspheres for hepatocellular carcinoma. J Nucl Med 2001;42:1587-9
83. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intra-arterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583-92
84. Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects. Q J Nucl Med Mol Imaging 2004;48:317-25
85. Roselli M, Greiner JW, Nieroda CA, Guzdagni F. New biological strategies to improve radioimmunodetection/therapy effectiveness. In: Riva P, editor. Cancer radioimmunotherapy. Harwood Academic Publishers; 1999. pp. 103-22